ID-085 / Idorsia - LARVOL DELTA

Cholesterol-Lowering Effects of BMS-303141 Analogues via Inhibition of Adenosine Triphosphate-Citrate Lyase. (PubMed, Curr Pharm Des) - "Based on the results, ID0085 appears to be the most promising therapeutic candidate for the treatment of hypercholesterolemia."

Journal • Cardiovascular • Dyslipidemia • Metabolic Disorders

IDS085. Treating Carbapenemase-Producing Enterobacterales with Novel and Repurposed Strategies. (ASM Microbe 2023) - "Antibiotics that have been repurposed to treat these problematic pathogens will also be reviewed. Identify novel therapies used to treat CPEs Define alternative repurposed antibiotics used to CPEs Understand the benefits and caveats of the different approaches used to treat CPEs"

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: Idorsia Pharmaceuticals Ltd.; Recruiting ➔ Completed

Clinical • Trial completion

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: Idorsia Pharmaceuticals Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open